390 likes | 561 Views
Comparative quantitative evaluation of the XIAP, Survivin & Ki67 transcript levels in urine & tissue samples of bladder cancer patients. Introduction. Bladder cancer (BCa): 5th most common cancer in European men & 6th leading cause of death
E N D
Comparative quantitative evaluation of the XIAP, Survivin & Ki67 transcript levels in urine & tissue samples of bladder cancer patients
Introduction • Bladder cancer (BCa): 5th most common cancer in European men & 6th leading cause of death • Cystoscopy & urine cytology: current gold standards for diagnosis & surveillance of BCa • No ideal tumor marker for non-invasive diagnostic & surveillance at the moment
Introduction • Survivin inhibitor of apoptosis protein (IAP) that is selectively over-expressed in most human malignancies • Objectives • determine suitability of Survivin as diagnostic, surveillance (and prognostic) marker of BCa • compare the utility of Survivin to other potential tumor markers e.g. Ki67 and XIAP
Materials & Methods • Prospective study • Single, tertiary level referral centre • January - June 2006 • Inclusion criteria • patients undergoing transurethral resection (TUR) for newly diagnosed BCa, recurrent BCa & cystoscopically suspicious bladder lesions
Materials & Methods • Exclusion criteria • Patients with PCa, IDC, UTI • Controls • BPH patients • Cystitis patients • Healthy volunteers
Materials & Methods • BCa patients • Pre-operative urine sample • Intra-operative tumor tissue & “normal appearing” bladder mucosa • Post-operative urine sample (1 POD) > for each session of TUR • Controls • 1 urine sample
Materials & Methods • Quantitative evaluation of urinary & tissue levels of Survivin, XIAP & Ki67 • Normalized ratios of Survivin, XIAP & Ki67 correlated with clinicopathological data
Results • Reference genes : HPRT & TBP • Negative correlation between reference gene expression & urinary contamination by RBCs & WBCs
BCa patients 65 recruited 6 pts with both BCa & Pca, excluded from analysis > 59 pts analysed Age (median)= 69yrs (34 – 89) M:F= 39: 20 (66.1% : 33.9%) Newly dx: BCa recurr= 54: 5 (91.5% : 8.5%) PSA (median; 36 pts)= 0.90 (0.16 – 12.54)
BCa patients Stage @ diagnosis (59) • No tumour (11) 18.6% • Superficial (38) = Ta+T1 64.5% • Invasive (10) = T2 16.9% Grade @ diagnosis (59) • No tumour (11) 18.6% • Low (14) = G1 23.8% • High (34) = G2+G3 57.6%
BCa patients • cis • Pos: neg= 5: 54 (8.5% : 91.5%) • All with cis harbour high grade (G2/ G3) disease as well • Cytology • Sensitivity= 65.2%; Specificity= 80.0% • PPV= 83.3%; NPV= 60.0%
BCa patients • 59 primary TURBT 42 second op (33 sec TUR, 9 cystec) 8 third op (6 tertiary TUR, 2 cystec)
Tumor markers in urine of BCa patients & controls • For healthy controls the absent values were substituted by zero Median values presented
Tumor markers vs BCa stage Median values presented
Tumor markers vs BCa grade Median values presented
Tumor markers at primary & secondary TURBT Median values presented
Tumor markers for unpaired tissue samples Median values presented
Tumor markers for paired tissue samples Median values presented
Ratio Tu / Tf Median values presented